Current status of clinical trials assessing oncolytic virus therapy for urological cancers

Area of Science:

• Oncology
• Virology
• Immunotherapy

Background:

• Oncolytic virus therapy utilizes viruses to selectively infect and destroy cancer cells, sparing normal tissues.
• Talimogene laherparepvec (T-VEC), an oncolytic herpes simplex virus type 1, is FDA-approved for melanoma, indicating therapeutic potential.
• Urological cancers represent a significant area for exploring novel therapeutic strategies.

Purpose of the Study:

• To review the current clinical trial landscape of oncolytic virus therapy for major urological malignancies.
• To highlight the types of oncolytic viruses being investigated in clinical trials for prostate, bladder, and renal cell cancers.
• To assess the future prospects of oncolytic virus therapy as a treatment modality for urological cancers.

Main Methods:

• Systematic review of published preclinical and clinical studies on oncolytic virus therapy in urological cancers.
• Analysis of ongoing and completed clinical trials involving various oncolytic viruses.
• Inclusion of data on herpes simplex virus type 1, adenoviruses, reoviruses, vaccinia virus, Sendai virus, and Newcastle disease virus.

Main Results:

• Several oncolytic viruses have demonstrated efficacy in preclinical models of prostate, bladder, and renal cell cancers.
• Clinical trials, including a Phase I trial of G47Δ (herpes simplex virus type 1) for prostate cancer, have been initiated.
• Diverse viral platforms are being explored, showcasing the breadth of research in this field.

Conclusions:

• Oncolytic virus therapy is emerging as a significant therapeutic approach for urological cancers.
• Continued clinical investigation is crucial to establish the role of oncolytic viruses in treating these malignancies.
• Oncolytic virus therapy holds considerable potential to become a major treatment option for urological cancers in the near future.